The global rapid-acting insulin market size was valued at USD 6.77 billion in 2021. It is expected to reach USD 9.72 billion by 2030, growing at a CAGR of 4.1% during the forecast period (2022–2030).
Insulin analogs classified as rapid-acting have a significantly quicker onset of action than that other insulin analogs. It is necessary to administer the medication between five and ten minutes before eating because these kinds of insulin analogs enter the bloodstream within minutes of injection. In addition, because rapid-acting insulins take effect very rapidly, people who make them run a greater risk of experiencing hypoglycemia. Fiasp, Humalog, NovoRapid, and Apidra are just a few of the rapid-acting insulins currently on the market.
It has been discovered that a patient with diabetes has a mortality rate significantly higher than that of the general population. A diabetic person will most likely pass away within a few days if they do not receive rapid-acting insulin regularly or if their supply is inconsistent. The manufacturing companies of insulin are taking various steps to make the product available to patients, which will drive the market's growth.
|Market Size||USD 9.72 billion by 2030|
|Fastest Growing Market||Europe|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
Sedentary and unhealthy lifestyles raise the risks of all causes of mortality, including colon cancer, high blood pressure, osteoporosis, lipid disorders, depression, and anxiety. They also double the risk of cardiovascular diseases, diabetes, and obesity. According to the WHO (World Health Organization), sixty to eighty-five percent of people in both developed and developing countries lead sedentary and unhealthy lifestyles, which is a matter of concern. Along with cardiovascular disease, cancer, and respiratory diseases, diabetes is responsible for most disease burden and premature mortality in the European region. The global prevalence of diabetes is rising, and the WHO predicts that by 2030, diabetes will be the seventh leading cause of death. In addition, diabetes risk factors include overweight or obesity, an unhealthy diet, and physical inactivity, which account for approximately 80 percent of the rise in diabetes prevalence. Consequently, sedentary and unhealthy lifestyles contribute to the expansion of the market.
One of the key factors driving the growth of the rapid-acting insulin market is the increasing prevalence of diabetes across the globe. This is due to lifestyle changes, increased alcohol consumption, obesity, urbanization, and hypertension. The growth of the rapid-acting insulin market is anticipated to be bolstered by a rise in the global diabetes population and an increase in research and development (R&D) activities in human insulin development by various government and private organizations. In addition, advanced diabetes treatments increase the efficacy of human insulin, reduce the diabetes burden, and reduce the risk of diabetes-related disorders such as diabetes-associated blindness, kidney disease, heart attacks, and amputations. Increasing investments in research and development (R&D) for human recombinant insulin are anticipated to drive the demand for insulin used in managing diabetes.
There is a possibility that rapid-acting insulins such as Humalog, fiasp, Novo rapid, and Apidra could occasionally have several unfavorable effects on the patient's health. Adults having type 1 diabetes are typically treated with rapid-acting insulin injections like Humalog (insulin lispro), a hormone naturally produced by the body. In most cases, another form of long-acting insulin is combined with Humalog administration. In addition, oral medications are often combined with Humalog when treating adults with type 2 diabetes. For instance, the most typical adverse effect of insulin lispro medications like Humalog is a condition known medically as hypoglycemia (low blood sugar). In addition, people with low blood sugar may experience symptoms such as a headache, nausea, hunger, confusion, drowsiness, weakness, dizziness, blurred vision, fast heartbeat, sweating, tremor, difficulty concentrating, confusion, or seizures (convulsions). As a result of these adverse effects, the market for rapid-acting insulin will experience slower growth.
It is anticipated that countries located in developing regions will have potential growth opportunities available to them in the coming years. The expansion can be attributed to their large population bases with unmet healthcare needs, improved healthcare infrastructure, increased government support, and an increase in the amount spent on healthcare. A significant portion of the population in developing and underdeveloped economies has not yet been diagnosed with diabetes. As a result, there is currently a higher need for diabetes management products in these regions. In addition, numerous key players, including Eli Lilly and Company, Novo Nordisk AS, and Sanofi, have entered these emerging markets. Therefore, it is likely that this population of people with diabetes will provide new opportunities for expanding the rapid-acting insulin market.
The global rapid-acting insulin market is segmented into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is anticipated to hold a dominant share of the global rapid-acting insulin market. The growth of the North American rapid-acting insulin market is primarily driven by a developed healthcare infrastructure, a more prominent target population, ease of drug availability, and favorable healthcare reimbursement policies.
Europe holds the second-largest share in the global rapid-acting insulin market. The increase in the diabetic population, the strong presence of key players such as ADOCIA SAS, Novo Nordisk A/S, and Sanofi S.A., and the surge in adoption of rapid-acting insulin all contribute to the market's expansion. In addition, the increase in Europe's elderly population presents significant opportunities for the growth of the market for rapid-acting insulin.
Due to factors like growing geriatric and target populations, an increase in collaborations for the development of biosimilars, geographic expansion of key players, and active involvement of the government and nonprofit sectors in the market space, Asia Pacific is predicted to experience significant growth during the forecast period. Additionally, health awareness campaigns and scientific conferences may aid regional market expansion to manage this disease.
The global rapid-acting insulin market is segmented based on product type, indication, and distribution channel.
Based on product type, the global market is segregated into insulin lispro, insulin aspart, and insulin glulisine.
The insulin lispro segment is the highest contributor to the market. The lispro insulin segment is anticipated to grow with the largest share throughout the forecast period due to the product's better advantages, including quicker subcutaneous absorption, an earlier and greater insulin peak, and a shorter duration of action. In addition, several companies have launched new products to methodically improve the breadth and depth of their product offerings, contributing significantly to the market's expansion. Aspart insulin is fast-acting because it is absorbed by the body and can act more quickly than human insulin. It is comparable to lispro insulin, which will further stimulate market expansion.
Based on the indication, the global market is fragmented into type 1 diabetes and type 2 diabetes.
The type 2 diabetes segment held the largest market share. Type 2 diabetes occurs when a patient's body cannot produce enough insulin to meet demand or when body cells cannot respond to insulin. Increased urbanization, poor diet, and decreased physical activity increased the prevalence of type 2 diabetes. In addition, some rapid-acting insulin products are used to treat type 2 diabetes, such as Humalog, Apidra, Kixelle, and Lyumjev. Type 2 diabetes has a higher prevalence rate than type 1, making it the most significant contributor to market expansion.
Due to the high level of insulin dependency among these patients, type 1 diabetes mellitus will account for the largest application category in 2022. The condition is more serious than type 2 diabetes. Around 10% of people with diabetes, according to the International Diabetes Federation, have type 1 diabetes.
Based on distribution channels, the global market into hospitals, drug stores, retail pharmacies, and online providers.
The drug stores and retail pharmacies segment is the highest contributor to the market. The drugstore and retail pharmacy provides both brand-name and generic drugs per prescription. Due to the widespread availability of drug stores and retail pharmacy stores, many customers rely on them. Additionally, these pharmacies offer alternative insulin options if prescribed ones are unavailable. In addition, retail pharmacies can monitor stock, encourage customers to purchase medications, recommend prescriptions, and offer improved financial and debt management to patients, encouraging consumers to shop at retail pharmacy stores. Thus, these factors are anticipated to contribute to market expansion.
Due to the expanding disease load, the viability of patients receiving home care, and the numerous discounts provided by retail pharmacies, the retail pharmacy segment dominated the total market in 2022. In the United States, the market has seen retail pharmacy chains consolidate. Additionally, moderate growth in the hospital pharmacy market is anticipated. Factors like the increase in diabetic individuals being admitted to hospitals fuel this market sector.
The global rapid-acting insulin market’s major key players are